Hep C Sofosbuvir/Daclatasvir Combo Promising for COVID-19

Authors
Category Primary study
Web pageMedscape
Year 2020
An inexpensive two-drug regimen of sofosbuvir (Sovaldi, Gilead Sciences) plus daclatasvir (Daklinza, Bristol-Myers Squibb) taken for 14 days significantly reduced time to recovery from COVID-19 and improved survival in people hospitalized with severe disease, research from an open-label Iranian study shows.
Epistemonikos ID: 752ae3cc92721ba02f2046c7c14d587a2a971c68
First added on: Feb 21, 2021